Asia
Lotus Pharmaceutical Calls NT$30 Billion Revenue Outlook Report 'Speculative'
Lotus Pharmaceutical (TPE:1795) clarified a Commercial Times report that said institutional investors expect its full-year revenue to exceed NT$30 billion, calling the outlook speculative.The company advised investors to refer to its filings on the Market Observation Post System (MOPS) for official information, according to a Tuesday Taiwan Exchange filing.
TPE:1795
